FDA Issues Complete Response Letter for GSK's Cervical Cancer Vaccine
Posted on: Wednesday, 19 December 2007, 06:00 CST
GlaxoSmithKline has received a complete response letter from the FDA related to its application for the cervical cancer vaccine, Cervarix.
A complete response letter is issued by FDA's Center for Biologics Evaluation and Research when the review of a file is completed and questions remain to be answered prior to approval.
GlaxoSmithKline (GSK) has said that it will work closely with the FDA to prepare its response, which it intends to submit to the agency as soon as possible. The application filed for the GSK cervical cancer vaccine included safety, efficacy and immune response data from clinical trials involving almost 30,000 females aged between 10 and 55 from ethnically and racially diverse populations.
Barbara Howe, vice president and director, North American vaccine development, GSK, said: "We have already started addressing the questions and will be engaged in discussions with the FDA to finalize our responses. Our discussions with the agency continue to be positive and constructive, and we are working diligently to resolve any outstanding questions to bring Cervarix to the US market."
Source: Datamonitor
Related Articles
- Video: FDA Approves GSK's Hib Vaccine, Hiberix(R)
- Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
- FDA Approves Glaxo's Rotarix Vaccine in Infants
- Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
- EPIX Receives FDA Response to Vasovist(TM) Appeal
- Analysis: FDA Delays GSK Cancer Vaccine
- FDA Tests Bird-Flu Vaccine Effectiveness
- Vical Vaccine Adjuvant Boosts Immune Response to Influenza Vaccine
- FDA Approval of Merck Vaccine Delayed
- Immune Response to Influenza Vaccine is Maintained in MS Patients Treated With Rebif(R)
 |
 |
User Comments (0)
RSS Feeds